iRay Technology Co., Ltd.

iRay Technology Co., Ltd. has experienced notable stock performance, gaining 3.66% on June 15, 2026, and achieving a 14.93% increase over the past month. Despite facing challenges such as negative quarterly results and rising raw material costs, the company has shown resilience in the Pharmaceuticals & Biotechnology sector.

iRay Technology Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite a strong monthly gain, the company has reported negative results for three consecutive quarters and a year-over-year profit drop, raising concerns about its long-term growth amid rising costs.

iRay Technology Co., Ltd. faced a notable decline in stock performance on June 5, 2026, amid challenges in the Pharmaceuticals & Biotechnology sector. The company has reported negative results for three consecutive quarters, with rising raw material costs and a high price-to-book ratio, while maintaining a significant market capitalization.

iRay Technology Co., Ltd. faced a notable stock decline on June 1, 2026, despite a strong annual return of 58.59%. The company has encountered financial challenges, including a 27.8% profit drop and negative results for three consecutive quarters, while maintaining a market capitalization of CNY 28,291 million.

iRay Technology Co. has seen a notable increase in its stock price, achieving a significant rise over the past week and month. Despite facing challenges such as declining profits and negative quarterly results, the company's market capitalization remains substantial, indicating its strong position in the Pharmaceuticals & Biotechnology sector.

iRay Technology Co., Ltd. has experienced notable short-term gains, with a 4.21% increase today and a 27.15% rise over the past week. Despite impressive year-to-date growth of 82.13%, the company faces challenges in long-term metrics, including negative results for the last three quarters and modest annual growth rates.

iRay Technology Co., Ltd. experienced a notable gain on May 21, 2026, reaching an intraday high of CNY 188.60. The stock has surged significantly over the past week and month, while year-to-date performance shows substantial growth. However, the company faces long-term challenges, including recent negative quarterly results.

iRay Technology Co., Ltd. has recently experienced a change in its evaluation, reflecting shifts in technical and valuation metrics. While the company has shown a significant return over the past year, it faces challenges such as declining profits and mixed signals in its market performance.

iRay Technology Co., Ltd. saw a significant rise in stock performance on April 16, 2026, with a notable intraday high. Over the past week, the company outperformed the broader market, although it faced challenges with a year-over-year decline. It operates in the Pharmaceuticals & Biotechnology sector with a substantial market capitalization.

iRay Technology Co. has seen a significant rise in its stock today, reaching an intraday high. However, its performance over the past week and month shows declines, despite a year-to-date increase. The company has a market cap of CNY 24,130 million and a price-to-earnings ratio of 48.00.

iRay Technology Co., Ltd. saw a significant stock decline, contrasting with the broader market's performance. The company has faced challenges, including three consecutive quarters of negative results and slowing net sales growth. Rising raw material costs have further pressured its financials, despite a strong annual return.

iRay Technology Co., Ltd. has demonstrated notable stock performance, achieving a significant gain on March 24, 2026. Over the past year, the company has outperformed the China Shanghai Composite index, despite facing recent challenges. Its financial metrics indicate a strong market capitalization and low debt levels.

iRay Technology Co. faced a challenging trading day on March 23, 2026, with a notable decline in stock value. Despite recent setbacks, the company has shown strong annual performance, significantly outperforming the China Shanghai Composite. However, it has reported negative results for three consecutive quarters, indicating ongoing difficulties.

iRay Technology Co., Ltd. saw its stock price decline significantly today, contrasting with the broader market. Despite a strong annual return, the company has reported negative results for three consecutive quarters, raising concerns about its growth potential amid falling profits and rising costs in the Pharmaceuticals & Biotechnology sector.

iRay Technology Co., Ltd. saw a significant stock decline today, contrasting with the broader market's performance. Despite recent gains and strong year-to-date returns, the company faces challenges, including consecutive quarterly losses and rising raw material costs, while maintaining a high price-to-earnings ratio in the Pharmaceuticals & Biotechnology sector.

iRay Technology Co. has experienced notable stock performance, gaining 4.38% on October 24, 2025, and reaching an intraday high of CNY 120.28. Despite a 27.8% decline in profits over the past year, the company has shown strong sales growth and impressive year-to-date returns.

iRay Technology Co., Ltd. faced a notable stock decline on October 13, 2025, amid challenges in the Pharmaceuticals & Biotechnology sector. Despite a strong year-to-date performance, the company reported a significant profit drop and maintains a high price-to-earnings ratio, reflecting its premium valuation amidst market volatility.

iRay Technology Co., Ltd. saw its stock price decline significantly today, contrasting with the broader market. Despite a strong annual return of over 61%, the company has faced challenges, including three consecutive quarters of negative results and a notable profit decline. Financial metrics indicate a high valuation and conservative leverage.